PDZK1/NHERF3 Differentially Regulates Corticotropin-releasing Factor Receptor 1 and Serotonin 2A Receptor Signaling and Endocytosis

Cellular Signalling

Volumn 27, Issue 3, 2015, Pages 519-531

  Walther, Cornelia ^a   Caetano, Fabiana A ^a   Dunn, Henry A ^a,b   Ferguson, Stephen S G ^a,b  

^a ROBARTS RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Corticotrophin releasing factor receptor 1; Mood disorders; Protein interaction; Serotonin receptor 2A; Signaling; Trafficking

Indexed keywords

CARRIER PROTEINS AND BINDING PROTEINS; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; CYCLIC AMP; INOSITOL PHOSPHATE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; SEROTONIN 2A RECEPTOR; SODIUM PROTON EXCHANGE REGULATORY COFACTOR 3; UNCLASSIFIED DRUG; CARRIER PROTEIN; CORTICOTROPIN RELEASING FACTOR RECEPTOR; PDZK1 PROTEIN, HUMAN; SMALL INTERFERING RNA;

ARTICLE; BINDING SITE; CELL MEMBRANE; CONTROLLED STUDY; EMBRYO; ENDOCYTOSIS; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS; GENETICS; HEK293 CELL LINE; METABOLISM; PDZ DOMAIN; PHOSPHORYLATION; PROTEIN DOMAIN; RNA INTERFERENCE;

CARRIER PROTEINS; CELL MEMBRANE; CYCLIC AMP; ENDOCYTOSIS; HEK293 CELLS; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PDZ DOMAINS; PHOSPHORYLATION; PROTEIN INTERACTION DOMAINS AND MOTIFS; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION;

EID: 84922593740     PISSN: 08986568     EISSN: 18733913     Source Type: Journal    
DOI: 10.1016/j.cellsig.2014.12.019     Document Type: Article

References (59)

1. Leonard B.E. Eur.Psychiatr. 2005, 20(Suppl. 3):S302-306.
2. Lanfumey L., Mongeau R., Cohen-Salmon C., Hamon M. Neurosci. Biobehav. Rev. 2008, 32:1174-1184.
3. Hale M.W., Shekhar A., Lowry C.A. Cell. Mol. Neurobiol. 2012, 32:695-708.
4. Vale W., Spiess J., Rivier C., Rivier J. Science 1981, 213:1394-1397.
5. Lupien S.J., McEwen B.S., Gunnar M.R., Heim C. Nat. Rev. Neurosci. 2009, 10:434-445.
6. Van Praag H.M. Neurotox. Res. 2002, 4:531-555.
7. Booij L., Wang D., Levesque M.L., Tremblay R.E., Szyf M. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2013, 368:20120251.
8. Barnes N.M. Curr. Opin. Pharmacol. 2011, 11:1-2.
9. Chalmers D.T., Lovenberg T.W., Grigoriadis D.E., Behan D.P., De Souza E.B. Trends Pharmacol. Sci. 1996, 17:166-172.
10. Dautzenberg F.M., Hauger R.L. Trends Pharmacol. Sci. 2002, 23:71-77.
11. Catapano L.A., Manji H.K. Biochim. Biophys. Acta 2007, 1768:976-993.
12. Chaki S., Nakazato A., Kennis L., Nakamura M., Mackie C., Sugiura M., Vinken P., Ashton D., Langlois X., Steckler T. Eur. J. Pharmacol. 2004, 485:145-158.
13. Overstreet D.H., Griebel G. Eur. J. Pharmacol. 2004, 497:49-53.
14. Fribourg M., Moreno J.L., Holloway T., Provasi D., Baki L., Mahajan R., Park G., Adney S.K., Hatcher C., Eltit J.M., Ruta J.D., Albizu L., Li Z., Umali A., Shim J., Fabiato A., MacKerell A.D., Brezina V., Sealfon S.C., Filizola M., Gonzalez-Maeso J., Logothetis D.E. Cell 2011, 147:1011-1023.
15. Brady A.E., Limbird L.E. Cell. Signal. 2002, 14:297-309.
16. Dhami G.K., Ferguson S.S.G. Pharmacol. Ther. 2006, 111:260-271.
17. Ferguson S.S.G. Trends Pharmacol. Sci. 2007, 28:173-179.
18. von Zastrow M. Biochem. Soc. Trans. 2001, 29:500-504.
19. Magalhaes A.C., Dunn H., Ferguson S.S.G. Brit. J. Pharmacol. 2012, 165:1717-1736.
20. Arzt E., Holsboer F. Trends Pharmacol. Sci. 2006, 27:531-538.
21. Dautzenberg F.M., Higelin J., Teichert U. Eur. J. Pharmacol. 2000, 390:51-59.
22. Hauger R.L., Risbrough V., Brauns O., Dautzenberg F.M. CNS Neurol. Disord. Drug Targets 2006, 5:453-479.
23. Dautzenberg F.M., Hauger R.L. Trends Pharmacol. Sci. 2002, 23:71-77.
24. Holmes K., Babwah A.V., Dale L.B., Poulter M.O., Ferguson S.S.G. J. Neurochem. 2006, 96:934-949.
25. Raymond J.R., Mukhin Y.V., Gelasco A., Turner J., Collinsworth G., Gettys T.W., Grewal J.S., Garnovskaya M.N. Pharmacol. Ther. 2001, 92:179-212.
26. Romero G., von Zastrow M., Friedman P.A. Adv. Pharmacol. 2011, 62:279-314.
27. Dunn H.A., Walther C., Godin C.M., Hall R.A., Ferguson S.S. J. Biol. Chem. 2013, 288:15023-15034.
28. Dunn H.A., Walther C., Yuan G.Y., Caetano F.A., Godin C.M., Ferguson S.S.G. Mol. Pharmacol. 2014, 86:275-283.
29. Ardura J.A., Friedman P.A. Pharmacol. Rev. 2011, 63:882-900.
30. Magalhaes A.C., Holmes K.D., Dale L.B., Comps-Agrar L., Lee D., Yadav P.N., Drysdale L., Poulter M.O., Roth B.L., Pin J.P., Anisman H., Ferguson S.S. Nat. Neurosci. 2010, 13:622-629.
31. Chen Y., Li M. Neuropharmacology 2005, 49:1026-1041.
32. Kocher O., Comella N., Tognazzi K., Brown L.F. Lab. Investig. 1998, 78:117-125.
33. Kocher O., Krieger M. Curr. Opin. Lipidol. 2009, 20:236-241.
34. Lamprecht G., Seidler U. Am. J. Physiol. Gastrointest. Liver Physiol. 2006, 291:G766-777.
35. Kato Y., Sai Y., Yoshida K., Watanabe C., Hirata T., Tsuji A. Mol. Pharmacol. 2005, 67:734-743.
36. Wang S., Yue H., Derin R.B., Guggino W.B., Li M. Cell 2000, 103:169-179.
37. Barak L.S., Salahpour A., Zhang X., Masri B., Sotnikova T.D., Ramsey A.J., Violin J.D., Lefkowitz R.J., Caron M.G., Gainetdinov R.R. Mol. Pharmacol. 2008, 74:585-594.
38. Ferguson S.S., Caron M.G. Methods Mol. Biol. 2004, 237:121-126.
39. Galehdar Z., Swan P., Fuerth B., Callaghan S.M., Park D.S., Cregan S.P. J. Neurosci. 2010, 30:16938-16948.
40. Steckley D., Karajgikar M., Dale L.B., Fuerth B., Swan P., Drummond-Main C., Poulter M.O., Ferguson S.S., Strasser A., Cregan S.P. J. Neurosci. 2007, 27:12989-12999.
41. Xia Z., Gray J.A., Compton-Toth B.A., Roth B.L. J. Biol. Chem. 2003, 278:21901-21908.
42. Bauch C., Koliwer J., Buck F., Honck H.H., Kreienkamp H.J. PLoS One 2014, 9:e88529.
43. Kim J.K., Kwon O., Kim J., Kim E.K., Park H.K., Lee J.E., Kim K.L., Choi J.W., Lim S., Seok H., Lee-Kwon W., Choi J.H., Kang B.H., Kim S., Ryu S.H., Suh P.G. J. Biol. Chem. 2012, 287:21012-21024.
44. Turner E.C., Mulvaney E.P., Reid H.M., Kinsella B.T. Mol. Biol. Cell 2011, 22:2664-2679.
45. Wente W., Stroh T., Beaudet A., Richter D., Kreienkamp H.J. J. Biol. Chem. 2005, 280:32419-32425.
46. He J., Bellini M., Inuzuka H., Xu J., Xiong Y., Yang X., Castleberry A.M., Hall R.A. J. Biol. Chem. 2006, 281:2820-2827.
47. Jones K.A., Srivastava D.P., Allen J.A., Strachan R.T., Roth B.L., Penzes P. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:19575-19580.
48. Sabio G., Arthur J.S., Kuma Y., Peggie M., Carr J., Murray-Tait V., Centeno F., Goedert M., Morrice N.A., Cuenda A. EMBO J. 2005, 24:1134-1145.
49. Gardner L.A., Naren A.P., Bahouth S.W. J. Biol. Chem. 2007, 282:5085-5099.
50. Kim E., Sheng M. Nat. Rev. Neurosci. 2004, 5:771-781.
51. Naisbitt S., Kim E., Tu J.C., Xiao B., Sala C., Valtschanoff J., Weinberg R.J., Worley P.F., Sheng M. Neuron 1999, 23:569-582.
52. Kim M.J., Futai K., Jo J., Hayashi Y., Cho K., Sheng M. Neuron 2007, 56:488-502.
53. Wang B., Yang Y., Abou-Samra A.B., Friedman P.A. Mol. Pharmacol. 2009, 75:1189-1197.
54. Balasubramanian S., Fam S.R., Hall R.A. J. Biol. Chem. 2007, 282:4162-4171.
55. Guillaume J.L., Daulat A.M., Maurice P., Levoye A., Migaud M., Brydon L., Malpaux B., Borg-Capra C., Jockers R. J. Biol. Chem. 2008, 283:16762-16771.
56. Xu J., Paquet M., Lau A.G., Wood J.D., Ross C.A., Hall R.A. J. Biol. Chem. 2001, 276:41310-41317.
57. Gavarini S., Becamel C., Altier C., Lory P., Poncet J., Wijnholds J., Bockaert J., Marin P. Mol. Biol. Cell 2006, 17:4619-4631.
58. Ghosh M.G., Thompson D.A., Weigel R.J. Cancer Res. 2000, 60:6367-6375.
59. Goodbourn P.T., Bosten J.M., Bargary G., Hogg R.E., Lawrance-Owen A.J., Mollon J.D. Genes Brain Behav. 2014, 13:144-151.